TickerGuard
Buy Day today: Neutral (51) Mixed market breadth · no major macro event
IBRX

Immunitybio Inc

Healthcare · Biotechnology

8.50$ +0.2% vs. previous close Closing price · As of: Sep 18, 2026

Statements

Balance Sheet

Immunitybio Inc (IBRX) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 629 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet IBRX
Line item Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26
432 504 401 444 365 383 304 402 519 502 647 629
215 294 196 243 163 185 109 208 329 315 453 439
178 265 133 130 112 143 61 138 60 88 205 76
190 266 170 218 130 150 62 154 258 243 381 357
2.3 3.2 2.1 2.1 4.9 2.7 17 22 34 43 43 53
16 1.8 2.0 8.3 8.4 6.6 6.7 0.9 0.5 1.9
0.9 0.9 0.9 0.9 0.9 0.9 0.9 12
18 17 17 16 16 15 15 14 14 13 12 12
843 1,090 1,092 1,142 1,109 871 894 972 1,042 1,001 1,516 1,674
90 58 54 62 61 55 49 51 57 62 68 77
4.4 5.2 6.1 6.2 7.0 7.5 7.5 7.4 7.3 9.3 8.6 7.5
20 9.2 14 20 9.9 6.7 14 7.4 5.8 7.0 11 12
674 682 687 693 699 462 486 492 501 477 678 774
-412 -587 -692 -698 -745 -489 -591 -571 -524 -500 -870 -1,047
-2,728 -2,962 -3,096 -3,230 -3,316 -3,375 -3,505 -3,597 -3,665 -3,727 -4,359 -4,590
498 591 673 687 698 735 853 888 947 990 1,027 1,050

Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?